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Human carbonic anhydrases (CAs) are well studied targets for the development
of inhibitors for pharmaceutical applications. The crystal structure of human CA
II has been determined in complex with two CA inhibitors (CAIs) containing
conventional sulfonamide and thiadiazole moieties separated by a —CF2—o r
—CHNH2— spacer group. The structures presented here reveal that these
spacer groups allow novel binding modes for the thiadiazole moiety compared
with conventional CAIs.
1. Introduction
Carbonic anhydrases (CAs; EC 4.2.1.1) catalyze the interconversion
of carbon dioxide and bicarbonate. The mammalian  -class of CAs
(and the CA domains in more complex isoforms) are monomeric,
with a molecular weight of approximately 30 kDa. At present, 14
human-expressed isoforms of CA (HCA I–XIV) are known,
displaying widely varying tissue and subcellular distributions. They
differ with regard to expression patterns, expression levels, kinetic
properties and sensitivity to inhibitors (Tufts et al., 2003; Duda &
McKenna, 2004).
There is a wealth of information available on various CA inhibitors
(CAIs) and their kinetic and structural characterization (for a general
review, see Mansoor et al., 2000; Supuran et al., 2004). Brieﬂy, various
anions have historically been useful for studying the properties of the
Zn active site of CA and it has been shown that most monovalent
anions bind and inhibit CA activity to varying extents. These CAIs
bind to the Zn
2+ ion and interfere with the Zn-bound hydroxide
coordination by either displacing or replacing the hydroxide, thus
disrupting catalysis. A key residue in determining this displacement/
replacement is Thr199, which is thought to act as a hydrogen-bond
acceptor, stabilizing the Zn-bound hydroxide (Merz, 1990). Small
anionic inhibitors (e.g. azide and cyanate) can bind directly to the zinc
ion, thus substituting for the Zn-bound hydroxide. Inhibitors that
bind in this way maintain hydrogen bonding with Thr199 and parti-
cipate in the tetrahedral coordination of the Zn
2+ ion.
The most frequently used pharmaceutical class of CAIs are
aromatic and heterocyclic sulfonamides of the form R—SO2NH2 or
R—SO2NH(OH). Several crystal complex structures of various
sulfonamide inhibitors with various CAs have been determined and
show similar interactions. The ionized NH group binds directly to the
zinc and simultaneously donates a hydrogen bond to the hydroxyl
group of Thr199 and an O atom of the sulfonamide group interacts
with the amide backbone of Thr199 and in doing so displaces a
second solvent molecule in the active site, termed the ‘deep water’
(Nair et al., 1995). Fig. 1(a) shows the crystal structure of HCA II
complexed with the clinically used inhibitor acetazolamide (Nair et
al., 1995).
CAIs are commonly prescribed to treat a major symptom of
glaucoma: increased intraocular pressure. The inhibition of CA
suppresses the secretion of sodium, bicarbonate and aqueous humor,
thus lowering intraocular pressure (Maren, 1987). Clinically
important drugs for the treatment of glaucoma include Diamox
(acetazolamide) and Trusopt (dorzolamide) (Breinin & Gortz, 1954;
Lippaet al., 1992). Recently, aberrant expression of HCA IXhas been
shown to be associated with certain types of cancer, such as non-
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All rights reservedsmall-cell lung cancer and renal-cell carcinoma. It is thought that the
presence of CA in solid tumors may help cancerous cells to adapt to
hypoxic conditions and could increase the invasiveness of these
tumors (Wykoff et al., 2000; Giatromanolaki et al., 2001). Currently
prescribed CAIs such as acetazolamide are not very soluble and it is
believed that a drug with better water solubility would have improved
bioavailability for the topical treatment of glaucoma and possibly
cancer (Kim et al., 2005). In the search for CAIs with improved water
solubility and subsequent bioavailability, the Blackburn laboratory
has recently synthesized a series of heterocyclic sulfonamides that
have better water solubility than some of the conventional glaucoma
treatments yet still bind HCA II with nanomolar afﬁnity (Boyle et al.,
2005). These compounds have an additional spacer group, —CF2—o r
—CHNH2—, between the classically employed sulfonamide moiety
and the 1,3,4-thiadiazole ring (Figs. 1b and 1c, respectively).
We have determined the crystal structures of two of these
compounds, namely 2-amino-1,3,4-thiadiazolyl-5-diﬂuoromethane-
sulfonamide (BB3) and 2-dimethylamino-5-sulfonamido(amino-
methyl)-1,3,4-thiadiazole (TDM), in complex with HCA II to 1.6 and
1.15 A ˚ resolution, respectively. The structures show that the spacer
allows the CAIs more conformational freedom and as a consequence
alters the binding locations of the 1,3,4-thiadiazole ring within the
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Figure 1
Structure of the active site of HCAII complexed with inhibitors. (a) Acetazolamide (AZM), (b) BB3, (c) TDM; (d) superimposition of all three: BB3, blue; TDM, red; AZM,
green. The Zn atom is shown as a black sphere; side chains are as labeled. AZM coordinates were taken from PDB code 1yda (Nair et al., 1995). The red Fo   Fc electron-
density map shown in (a) and (b) is contoured at 2  and was calculated without the inhibitors present. Figures were generated and rendered with BobScript and Raster3D,
respectively (Esnouf, 1999; Merritt & Bacon, 1997).active site. These alternate binding modes are compared with other
CAIs. The use of such spacers may offer a method of making CAIs
that (i) are more soluble, (ii) have higher afﬁnity and (ii) provide new
binding modes of heterocyclic sulfonamides within the active-site
cavity whose ring could be modiﬁed to target speciﬁc amino-acid
differences between the various CA isoforms.
2. Experimental procedures
2.1. Expression and purification
Human CA II was expressed and afﬁnity-puriﬁed as described
elsewhere (Khalifah et al., 1977). The protein purity of fractions was
determined by silver-stained SDS–PAGE and fractions were pooled
accordingly. Prior to crystallization, the protein was dialyzed against
50 mM Tris–HCl pH 7.8 and subsequently concentrated to
 15 mg ml
 1 with Amicon Ultra centrifugation ﬁltration devices with
a molecular-weight cutoff of 10 kDa. Final concentrations were
determined by measuring the optical density at 280 nm and using a
molar absorbance of 5.5   10
4 M
 1 cm
 1.
2.2. Crystallization and diffraction data collection
Crystals of HCA II were grown using the hanging-drop method at
room temperature (McPherson, 1982). The crystallization drops were
prepared by mixing 5 ml protein ( 15 mg ml
 1 in 50 mM Tris–HCl
pH 7.8) with 5 ml precipitant solution (50 mM Tris–HCl pH 7.8, 2.6 M
ammonium sulfate) and were equilibrated against 1000 ml precipitant
solution. Useful crystals appeared within 5 d. The inhibitors BB3 and
TDM were solubilized in water to a ﬁnal concentration of 20 mM. Pre-
grown crystals of HCA II were then soaked in the presence of BB3
and TDM (at a ﬁnal concentration of  1 mM) for  24 h prior to data
collection. The crystals were quick-dipped in cryoprotectant (30%
glycerol in precipitant solution) before ﬂash-freezing them at 100 K
for X-ray data collection.
Diffraction data for the BB3-soaked HCA II crystals were
collected at Brookhaven National Laboratory beamline X29 on a
Quantum 315 CCD detector using a wavelength of 1.100 A ˚ .T h e
crystal-to-detector distance was set at 100 mm and oscillation images
were collected in 1  steps for a total of 297 images.
Diffraction data for the TDM-soaked HCA II crystals were
collected at Cornell High Energy Synchrotron Source beamline A1
on a Quantum 210 CCD detector using a wavelength of 0.978 A ˚ .T h e
crystal-to-detector distance was set at 100 mm and oscillation images
were collected in 1  steps for a total of 410 images. Data-collection
statistics are given in Table 1.
2.3. Structure determination and model refinement
X-ray diffraction data were indexed and scaled with DENZO and
SCALEPACK from the HKL program package (Otwinowski &
Minor, 1997). The structures were phased using molecular-
replacement methods with the software package Crystallography and
NMR System (CNS; Rossmann, 1990; Bru ¨nger et al., 1998). The
structure of HCA II (PDB code 1tbt) was used as the search model
(Fisher et al., 2005). After one cycle of rigid-body reﬁnement,
annealing by heating to 3000 K with gradual cooling, geometry-
restrained position reﬁnement and temperature-factor reﬁnement, Fo
  Fc Fourier electron-density OMIT maps were generated (Figs. 1b
and 1c). These maps clearly showed the position of the zinc and
inhibitors, which were subsequently built into their respective elec-
tron density. The PRODRG server (http://davapc1.bioch.dun-
dee.ac.uk/programs/prodrg/) was used to build coordinate and
topology ﬁles for the inhibitors (Schu ¨ttelkopf & van Aalten, 2004).
After initial reﬁnement in CNS, Rwork and Rfree were 0.193 and 0.224
for the BB3 complex and 0.225 and 0.236 for the TDM complex,
respectively.
Reﬁnement of both models continued using SHELXL97 in the
conjugate-gradient least-squares (CGLS) mode with SHELXL
default restraints used for the protein geometry (Sheldrick &
Schneider, 1997; Engh & Huber,1991). After each round of ten cycles
of CGLS reﬁnement, Fourier electron-density maps (Fo   Fc and
2Fo   Fc) were calculated and minor manual model manipulations
were performed using the molecular-graphics program Coot (Emsley
& Cowtan, 2004). After several rounds of reﬁnement, automated
water divination was performed with SHELX/WAT using Fo   Fc
electron-density OMIT maps with a 4  cutoff (Sheldrick &
Schneider, 1997). For the TDM complex all non-H atoms were
reﬁned anisotropically, whereas only the Zn and S atoms of the BB3
structure were reﬁned anisotropically, using the SHELXL97 default
anisotropic displacement parameters (Sheldrick & Schneider, 1997).
Manual model building included the modeling of alternate confor-
mations for Ile22 and Lys39 for the TDM-complex structure and the
addition/deletion of solvent molecules in both structures.
Reﬁnement of the structures continued until convergence of Rcryst
and Rfree was reached. The ﬁnal Rcryst and Rfree were 0.167 and 0.212
for the BB3 complex (1.6 A ˚ resolution) and 0.136 and 0.166 for the
TDM complex (1.15 A ˚ resolution), respectively. The model geome-
tries were analyzed by PROCHECK and inhibitor–enzyme inter-
actions were determined with LIGPLOT (Laskowski et al., 1993;
Wallace et al., 1995). All data-reﬁnement and ﬁnal model statistics are
given in Table 1.
3. Results and discussion
Here, we present the crystal structures of HCA II in complex with
two novel CAIs termed BB3 and TDM. These compounds differ from
protein structure communications
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Table 1
Data-collection, reﬁnement and ﬁnal model statistics.
Values in parentheses are for the highest resolution shell.
BB3 TDM
Data-collection statistics
Space group P21 P21
Unit-cell parameters (A ˚ ,  ) a = 42.3, b = 41.4,
c = 72.1,   = 104.1
a = 42.5, b = 41.6,
c = 72.7,   = 103.9
Resolution (A ˚ ) 20.0–1.60 (1.66–1.60) 20.0–1.15 (1.19–1.15)
Total No. of unique reﬂections 32031 (3154) 87379 (7896)
Completeness (%) 99.9 (100.0) 97.9 (89.3)
Redundancy 4.4 (4.3) 7.0 (4.1)
Overall I/ (I) 17.1 (4.2) 26.4 (4.7)
Rsym† 0.066 (0.209) 0.099 (0.323)
Reﬁnement statistics
Rcryst‡ 0.167 0.136
Rfree§ 0.212 0.166
R.m.s.d. for bond lengths (A ˚ ) 0.009 0.010
R.m.s.d. for angles ( ) 1.490 1.315
Average B factors (A ˚ 2)
Main chain 16.7 14.1
Side chains 23.2 17.5
Solvent 31.8 32.9
Inhibitor 21.5 16.5
Ramachandran statistics (%)
Most favored regions 87.9 88.8
Additionally allowed regions 12.1 11.2
No. of protein atoms 2039 2039
No. of solvent atoms 246 310
No. of inhibitor atoms 13 14
† Rsym =
P
jI  h Iij=
P
hIi.‡ Rcryst =
P   jFoj j Fcj
   =
P
jFoj.§ Rfree is calculated
the same way as Rcryst for data omitted from reﬁnement (5% of reﬂections for all data
sets).classical CAIs in that they contain a spacer group, —CF2—o r
—CHNH2—, between the sulfonamide moiety and 1,3,4-thiadiazole
ring for BB3 and TDM, respectively (Figs. 1b and 1c).
For both compounds the sulfonamide group maintains the same
anchoring function as for other inhibitors in that the ionized NH
group displaces the Zn-bound hydroxide and makes a hydrogen bond
with Thr199 OG1. The N3 of the sulfonamide group is 2.8 and 2.9 A ˚
from Thr199 OG1 in the BB3 and TDM structures, respectively.
However, it was observed that the spacer and 1,3,4-thiadiazole ring of
these compounds both adopt conformations in the active site of HCA
II that differ from those of other CAIs (Fig. 1).
For BB3, the —CF2— spacer permits conformational rotational
freedom between the sulfonamide and thiadiazole ring.Subsequently,
the thiadiazole ring of BB3 folds back and adopts a planar confor-
mation and forms a  -stacking interaction with His94 (Figs. 1b and
2a). This is a very different conﬁguration to that observed for other
CAIs, where the heterocyclic ring adopts a more extended confor-
mation that leads out of the active site. Acetazolamide is given here
as a contrasting example (Figs. 1a and 1d).
There are also several other observed interactions that mediate the
binding of BB3 to HCA II. The most interesting is the inferred
hydrogen bond (2.5 A ˚ )between F2ofBB3 andThr200 OG1(Fig. 2a).
In addition to the ﬂuorine hydrogen bond, the N1 and NH2 of the
thiadiazole ring directly hydrogen bond with Gln92 OE1 and
Asn67 OD1, respectively. An indirect hydrogen bond also exists
between NH2 of the thiadiazole ring and Asn62 ND2 through a
solvent molecule W369 (Fig. 2a).
In order to assess whether the  -stacking interaction with His94 of
the thiadiazole ring of BB3 is speciﬁc to the —CF2— spacer group,
the structure of compound TDM, which has a —CHNH2— spacer
group, was investigated (Fig. 1c). In this complex the thiadiazole ring
did not exhibit the  -stacking interaction with His94, but instead the
ring adopted a puckered conformation and a different position
relative to both BB3 and acetazolamide (Fig. 1d). N2 and N3 of the
thiadiazole ring hydrogen bond to solvent molecules W316 and
W599, which are in turn hydrogen bonded to Asn67. Interestingly,
unlike the ﬂuorine hydrogen bond observed for compound BB3, the
—CHNH2— spacer group does not appear to participate in any
stabilization interactions (Fig. 2b).
The observed differences between the binding modes of BB3 and
TDM may also in part arise from the dimethyl moiety of TDM, which
is located in the hydrophobic region of the active site that contains
amino acids Phe131 and Leu198 (Fig. 2b).
4. Conclusion
Carbonic anhydrases are a well studied target for the development of
new inhibitors for pharmaceutical research and applications. CAIs
are prescribed for the treatment of various diseases, such as glau-
coma, and have potential for cancer therapy. Historically, CAIs have
had poor solubility and bioavailability. We have determined the
crystal structures of two novel water-soluble CAIs in complex with
HCA II. These CAIs contain conventional sulfonamide and thia-
diazole moieties with the addition of spacer groups. The spacers
confer novel binding modes of thiadiazole within the active site that
have not been observed in other sulfonamide-based CAIs. The ability
to change the binding location of the heterocyclic ring of sulfonamide
CAI may provide a useful tool in the development of CA isoform-
speciﬁc inhibitors.
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